On the basis of recent clinical data suggesting that high-dose continuous @entity1487 ( @entity1487 ) is able to overcome resistance to @entity1487 bolus application in @entity356 , a phase II study was performed to evaluate the activity and @entity137 of weekly high-dose @entity1487 and @entity4181 plus biweekly alternating @entity632 and @entity900 as the first-line treatment in @entity1 with advanced @entity356 . Between October 1995 and September 1997, 24 consecutive @entity1 with locally advanced (n=4) or metastatic (n=20) @entity356 were treated with a combination of 500 mg/m2 @entity4181 as a 2-h infusion, followed by 2.0 g/m2 @entity1487 as a 24-h continuous infusion once weekly for 6 weeks, plus 20 mg/m2 @entity632 as a bolus application and 50 mg/m2 @entity900 as a 1-h infusion, week 1, 3 and 5 ( @entity1912 regimen). Response, @entity137 and survival data were evaluated. A total of 20 @entity1 were evaluable for response and 24 for @entity137 . Objective responses were observed in 11 @entity1 (55%) with no complete remission. Four @entity1 (20%) showed stabilization and 5 @entity1 (25%) experienced @entity74 . The median time to disease progression was 8 months and the overall duration of survival was 14 months. Myelosuppression was significant. In 2 @entity1 , grade 4 WHO @entity882 and @entity1431 / @entity417 respectively were registered, but there were no treatment-related @entity204 . We conclude that the weekly alternating @entity1912 regimen is effective in advanced @entity356 with tolerable @entity137 . However, significant myelotoxicity and frequent hospitalization suggest that @entity1912 should not be preferred to other regimens used in metastatic disease. Currently we intend to establish this regimen in the neoadjuvant setting in @entity1 with primary unresectable localized @entity356 .

A phase II study of weekly high-dose XXXX and @entity4181 plus biweekly alternating @entity632 and @entity900 for advanced @entity356 .

@entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anaemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1912 :: ('241', 'Gene') :: ['FLAP'] @entity74 :: ('MESH:D030342', 'Disease') :: ['progressive disease'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric carcinoma', 'gastric carcinomas'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil']
@entity1487 :: (MESH:D005472,Chemical) :: ['5-fluorouracil']
